• Users Online: 6
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
ORIGINAL ARTICLE
Year : 2020  |  Volume : 10  |  Issue : 3  |  Page : 110-114

Evaluation of the effect of perforan (Hypericum perforatum) on premenstrual syndrome severity of physical and behavioural symptoms in patients with premenstrual syndrome: A clinical randomised trial


1 Department of Midwifery, Nursing and Midwifery Sciences Development Research Center, Islamic Azad University, Najafabad Branch, Najafabad, Iran
2 Department of midwifery, School of Nursing and Midwifery, Tehran University of Medical Science, Tehran, Iran
3 Department of midwifery, Heshmatie Hospital, Isfahan University of Medical Science, Isfahan, Iran
4 Department of midwifery, School of Nursing and Midwifery, Shahid Beheshti University of Medical Sciences, Tehran, Iran
5 Department of Epidemiology and Biostatistics, Neuroscience Research Center, Qom University of Medical Sciences, Qom, Iran

Correspondence Address:
Haniyeh Abbassinya
School of Nursing and Midwifery, Tehran University of Medical Science, Tehran
Iran
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/AIHB.AIHB_16_20

Rights and Permissions

Background: Premenstrual syndrome (PMS) is an extensive group of emotional, behavioural and physical symptoms that occur before menstruation. It has a negative impact on activities of daily living, social activities, sexual functioning and quality of life. This study aimed to evaluate the effect of perforan (Hypericum perforatum) on the severity of physical and behavioural symptoms associated with PMS. Materials and Methods: In a triple-blind clinical trial, 93 students with PMS were randomly divided into two groups, including perforan and control (placebo) groups, and followed for three subsequent cycles. They took capsules daily in the first cycle for 1 month, and in the second and third cycles, they took capsules from 8 days pre-menstruation to 2 days post-menstruation and recorded the severity of physical and behavioural symptoms using a PMS questionnaire. Statistical analyses were performed using SPSS version 20. Repeated measures ANOVA, Chi-squared tests and independent t-tests were used to compare the mean scores of the two groups. Results: The data showed that there were no significant differences between the two groups before the intervention (P > 0.05). Nevertheless, the severity of physical and behavioural symptoms of PMS was significantly lower in the perforan group than the control group. This was the case 1, 2 and 3 months after consumption of perforan (P < 0.001). Moreover, a significant difference between the two groups in the decrease of PMS scores was observed by repeated measurement tests (P < 0.001). Conclusion: Perforan significantly reduces the severity of physical and behavioural symptoms of PMS. Therefore, perforan could be effective in the treatment of physical and behavioural symptoms of patients with PMS. Nevertheless, future studies are necessary to confirm these results.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed438    
    Printed18    
    Emailed0    
    PDF Downloaded60    
    Comments [Add]    

Recommend this journal